Therapeutic Advances in Endocrinology and Metabolism最新文献

{"title":"Hip axis length and non-hip cortical fragility fractures in young postmenopausal nonobese Caucasian women.","authors":"Irina Manuela Nistor, Simona Fica, Sorina Carmen Martin, Marius Lucian Mitrache, Theodor Eugen Oprea, Anca Elena Sirbu, Carmen Gabriela Barbu","doi":"10.1177/20420188251332082","DOIUrl":"10.1177/20420188251332082","url":null,"abstract":"<p><strong>Introduction: </strong>Although measuring bone mineral density (BMD) with dual X-ray absorptiometry (DXA) represents the standard of diagnosis and management of osteoporosis, there is a significant number of fragility fractures occurring in young patients without low BMD. Recently, clinical risk tools included hip axis length (HAL), a geometric parameter derived from the hip DXA scan, as a predictor of hip fractures in older postmenopausal women. This study aims to evaluate the relationship between HAL and other cortical bone fractures in young postmenopausal, clinically healthy women.</p><p><strong>Materials and methods: </strong>This study is a retrospective analysis of Lunar DXA scans of 206 normal or overweight Caucasian women aged 40-60, who had less than 10 years of menopause without secondary causes of osteoporosis, no prior osteoporosis diagnosis or medication, and no history of hip or vertebral fractures.</p><p><strong>Results: </strong>The 15 fractured women displayed statistically greater HAL values compared to the 191 non-fractured subjects (109.43 ± 6.44 vs 104.81 ± 5.32 mm, <i>p</i> = 0.002), even though there were no significant differences in age, body mass index, or BMD. The difference in HAL remained significant after adjusting for lumbar spine (LS) BMD and height (108.49 ± 1.23 vs 104.88 ± 0.34 mm, <i>p</i> = 0.005). HAL proved to be a fair indicator of non-hip, non-vertebral cortical fractures (area under curve = 0.720, <i>p</i> = 0.003), with a sensitivity of 86.7% and a specificity of 55.5%.</p><p><strong>Conclusion: </strong>HAL was positively associated with non-hip, non-vertebral cortical bone fragility fractures in young postmenopausal, clinically healthy women and had significantly greater values in the fractured subgroup even after adjusting for LS BMD and height.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251332082"},"PeriodicalIF":3.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis.","authors":"Haiyang Zhang, Ting Lu, Yinwei Li, Haixia Guan, Rebecca S Bahn, Huifang Zhou","doi":"10.1177/20420188251340137","DOIUrl":"10.1177/20420188251340137","url":null,"abstract":"<p><p>Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody that leads to immunosuppression through rapid depletion of B lymphocytes. It has been demonstrated to be useful in treating both thyroid eye disease (TED) and myasthenia gravis (MG), respectively. However, the effectiveness of RTX in concurrent TED and MG cases is unclear and not previously reported in the literature. In this study, we describe a 13-year-old girl who presented with a 10-year history of general MG and a 1-year history of Graves' disease, bilateral proptosis, eye motility restriction, and lagophthalmos. A comprehensive evaluation confirmed the diagnosis of concurrent TED and MG. Satisfactory effectiveness was observed after RTX treatment without side effects. Based on the described observations, we suggest that RTX should be further explored as a treatment option for patients with concurrent TED and MG.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251340137"},"PeriodicalIF":3.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic therapies for medullary thyroid carcinoma: state of the art.","authors":"Alejandro Román-González, Ines Califano, Marcio Concepción-Zavaleta, Fabian Pitoia, Sarimar Agosto Salgado","doi":"10.1177/20420188251336091","DOIUrl":"https://doi.org/10.1177/20420188251336091","url":null,"abstract":"<p><p>Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor accounting for less than 5% of all thyroid cancers. An estimated 25% of cases are familial secondary to a germline mutation on the rearranged during transfection proto-oncogene (<i>RET</i>); this gene can be present as a somatic mutation in approximately 40%-60% of sporadic MTC tumors. There is an existing genotype-phenotype correlation in the clinical behavior of MTC, with the RET M918T variant associated with aggressive disease. The current systemic treatment profile for progressive metastatic MTC involves antiangiogenics multikinase inhibitors (MKI), specifically cabozantinib and vandetanib, and high-specific RET inhibitor therapy. Decisions on the timing of systemic therapy initiation in this population should involve multidisciplinary care and individualization on a case-by-case scenario; a comprehensive evaluation of performance status, tumor burden, progression rate, medical comorbidities, possible medication interactions, and goals of care must be considered in a patient-centered approach. This review summarizes the evidence on the safety, efficacy, and limitations of systemic therapies for MTC; the aim is to empower clinicians with the knowledge to optimally manage patients with advanced, progressive, or metastatic MTC.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251336091"},"PeriodicalIF":3.9,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal patterns of inpatient hypoglycaemia are treatment-dependent.","authors":"Wharton O Y Chan, Paik Shia Lim, Alcey Li Chang Ang, Su-Yen Goh, Yong Mong Bee, Ming Ming Teh","doi":"10.1177/20420188251338749","DOIUrl":"https://doi.org/10.1177/20420188251338749","url":null,"abstract":"<p><strong>Background: </strong>Inpatient hypoglycaemia has been well studied around the world, and more tools are being developed to understand and predict hypoglycaemic episodes. Most published data, however, focuses on patient characteristics and predictions of whether a patient would have a hypoglycaemic episode during inpatient stay. There is a paucity of data concerning the timing, as well as types of diabetic medications used, surrounding a hypoglycaemia episode.</p><p><strong>Objectives: </strong>To characterise inpatient hypoglycaemia episodes by time and associated diabetes medications, on top of baseline patient characteristics.</p><p><strong>Design: </strong>Retrospective observational study of 425 hypoglycaemia episodes, over a 2 month period from two general internal medicine wards, in a tertiary medical hospital.</p><p><strong>Methods: </strong>A discrete hypoglycaemic episode is defined as a capillary blood glucose (CBG) reading of <4 mmol/L. Hypoglycaemic episodes were further sub-analysed by dividing them into three time frames - day (0801-1600), evening (1601-2359) and night (0000-0800).</p><p><strong>Results: </strong>In total, 425 hypoglycaemia episodes from 207 patients were analysed. Sulphonylurea (SU), premixed, basal and basal-bolus insulin regimens were associated with 31.8%, 30.4%, 15.1% and 5.9% of the hypoglycaemia episodes, respectively. All agents revealed significant intra-day differences (<i>p</i> < 0.05) except for the basal-bolus insulin regimen (<i>p</i> = 0.76). Basal insulin and sulphonylurea-associated hypoglycaemia occurred mostly in the midnight timeframe (0000-0800) at 65.6% and 47.4%, respectively, whereas premixed insulin-associated hypoglycaemia occurred mostly in the evening timeframe (1601-2359) at 51.2%. In total, there were significant differences in the distribution of hypoglycaemia across the three time frames associated with different diabetes medications (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>There are marked differences in the medications associated with inpatient hypoglycaemia at differing time points. These time points offer insight into appropriate CBG testing timings for different diabetes medications. Hence, stratified monitoring and strategic 3 a.m. testing of CBG for patients on sulphonylurea and basal insulin should be considered in tackling inpatient hypoglycaemia.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251338749"},"PeriodicalIF":3.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into body composition in pediatric craniopharyngioma patients after surgical treatment.","authors":"Hussein Zaitoon, Ori Eyal, Michal Yackobovitch-Gavan, Ravit Regev, Yael Issan, Jonathan Roth, Shlomi Constantini, Yael Lebenthal, Avivit Brener","doi":"10.1177/20420188251336087","DOIUrl":"https://doi.org/10.1177/20420188251336087","url":null,"abstract":"<p><strong>Background: </strong>Craniopharyngioma, a benign suprasellar tumor, is typically treated surgically with radiotherapy when indicated. Due to its proximity to the pituitary-hypothalamic region, patients often experience endocrine deficiencies.</p><p><strong>Objective: </strong>To explore the body composition components and their interaction with metabolic syndrome (MetS) components in pediatric craniopharyngioma patients after surgery.</p><p><strong>Design: </strong>Longitudinal single-center real-life study of 33 pediatric patients who were diagnosed with craniopharyngioma for which they underwent surgery between 2012 and 2024.</p><p><strong>Methods: </strong>Electronic medical reports were reviewed for clinical data, and a bioimpedance analysis (BIA) database was searched for body composition. Fifty-four BIA reports of 21 patients with craniopharyngioma were analyzed. The latest reported values were compared to those of 63 sex- and age-matched healthy controls. Changes in anthropometric measurements and indices of muscle and adiposity were assessed by linear mixed models.</p><p><strong>Results: </strong>Patients with craniopharyngioma exhibited higher adiposity compared to controls, with significantly elevated total body fat percentage (FATP; <i>p</i> < 0.001), trunk-to-total body FATP ratio (<i>p</i> = 0.012), and lower muscle-to-fat ratio (MFR) <i>z</i>-scores (<i>p</i> < 0.001). The appendicular skeletal muscle mass (ASMM) <i>z</i>-scores were similar. A sex- and age-adjusted model revealed that the diagnosis of MetS components was positively associated with FATP [odds ratio = 1.13, confidence interval (1.04, 1.23), <i>p</i> = 0.006]. Patients with craniopharyngioma demonstrated an increase in ASMM <i>z</i>-score over time (β = 0.14, SE = 0.04, <i>p</i> = 0.002) together with a decline in sex- and age-adjusted FATP (β = -0.99, SE = 0.41, <i>p</i> = 0.018).</p><p><strong>Conclusion: </strong>Despite struggling with obesity and hormonal deficiencies, survivors of craniopharyngioma showed favorable changes in body composition with appropriate medical interventions. Strategies to prevent metabolic complications and tailored hormone replacement therapies are essential for managing metabolic decline.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251336087"},"PeriodicalIF":3.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of morning basal serum cortisol for assessing adrenal reserve: a single-center experience from the United Arab Emirates.","authors":"Raya Almazrouei, Jawaher Alshamsi, Mohamed Abdelsalhen, Fatima Alkaabi, Adnan Agha","doi":"10.1177/20420188251335180","DOIUrl":"https://doi.org/10.1177/20420188251335180","url":null,"abstract":"<p><strong>Introduction: </strong>Adrenal insufficiency can be life-threatening due to the lack of cortisol elevation in times of stress. The short Synacthen test (SST) is the most common diagnostic test for adrenal insufficiency. This study aimed to assess the diagnostic performance of morning basal serum cortisol during an SST to assess normal adrenal reserve in a local Emirati population.</p><p><strong>Methods: </strong>We retrospectively analyzed the electronic medical records of adult patients who underwent morning SST to assess adrenal reserve between August 2012 and August 2022.</p><p><strong>Results: </strong>This study included 344 patients (201 women) with a mean age of 49.1 ± 22.6 years. Based on the previously published cutoff data for SST peak values at 30 min (408 nmol/L for Beckman-Access used from 2012 to 2017 and 402 nmol/L for Roche-Cobas Generation-II used since 2018) as a gold standard to identify patients with adequate adrenal reserve, 106 patients (30.8%) were diagnosed with adrenal insufficiency and 238 (69.2%) with adequate adrenal reserve. Using the receiver-operator characteristics curve for morning cortisol, we identified a cutoff of 332 nmol/L, which corresponded to adequate Synacthen stimulation with 100% specificity and 73% sensitivity. Morning cortisol levels of <96 nmol/L corresponded to suboptimal adrenal response to SST, with 95% specificity and 55% sensitivity.</p><p><strong>Conclusion: </strong>We propose that a morning cortisol cutoff of >332 nmol/L can help identify patients with adequate adrenal reserve, thereby avoiding unnecessary SSTs.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251335180"},"PeriodicalIF":3.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics investigation of prospective therapeutic targets for type 1 diabetes.","authors":"Yue-Yang Zhang, Qing-Tian Qiao, Bing-Xue Chen, Qin Wan","doi":"10.1177/20420188251337988","DOIUrl":"https://doi.org/10.1177/20420188251337988","url":null,"abstract":"<p><strong>Background: </strong>In recent years, the incidence of type 1 diabetes has been rising steadily, positioning its prevention and treatment as a central focus of global public health initiatives. Previous Mendelian randomization (MR) studies have investigated the relationship between proteomics and type 1 diabetes. Consequently, this study aims to identify prospective therapeutic targets for type 1 diabetes through a comprehensive multi-omics analysis.</p><p><strong>Methods: </strong>This study primarily utilized the MR method, drawing on genetic data from several large-scale, publicly accessible genome-wide association studies. Within this framework, we applied two-sample MR to evaluate the relationship between five omics components and type 1 diabetes. Finally, we conducted various sensitivity analyses and bidirectional MR to ensure the robustness and reliability of our findings.</p><p><strong>Results: </strong>The inverse variance weighted method revealed that, following false discovery rate correction, 39 plasma proteins and 3 plasma protein ratios exhibited significant associations with type 1 diabetes. The genetically predicted risk of type 1 diabetes ranged from 0.05 for RBP2 to 394.51 for FMNL1. Furthermore, 4-chlorobenzoic acid levels demonstrated a potential association with type 1 diabetes.</p><p><strong>Conclusion: </strong>Our research identified numerous omics components associated with type 1 diabetes. These findings offer novel insights into the disease's etiology, diagnosis, and treatment.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251337988"},"PeriodicalIF":3.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitation of the current Lin-Weiss-Bisceglia criteria in predicting poor prognosis in oncocytic adrenocortical neoplasms of uncertain malignant potential and oncocytoma diagnosed by the Lin-Weiss-Bisceglia criteria.","authors":"Byung-Chang Kim, HyeJin Han, Douk Kwon, Shin Jeong Pak, Hyeong Rok An, Won Woong Kim, Yu-Mi Lee, Seung Hun Lee, Jung-Min Koh, Jae Lyun Lee, Ki-Wook Chung, Dong Eun Song, Tae-Yon Sung","doi":"10.1177/20420188251328186","DOIUrl":"https://doi.org/10.1177/20420188251328186","url":null,"abstract":"<p><strong>Background: </strong>Oncocytic adrenocortical neoplasms (OANs) are extremely rare adrenal tumors whose diagnosis is challenging. This study aimed to identify risk factors for predicting poor prognosis in patients with OAN of uncertain malignant potential (OANUMP) and oncocytoma, OAN subtypes, and to evaluate the diagnostic utility of the current Lin-Weiss-Bisceglia (LWB) criteria.</p><p><strong>Methods: </strong>We retrospectively reviewed 14 patients diagnosed with OANUMP or oncocytoma after adrenalectomy from February 2002 to May 2022. Patients re-classified as oncocytic adrenocortical carcinoma by the LWB criteria were excluded. We compared the clinicopathological and radiological features between patients with and without recurrence.</p><p><strong>Results: </strong>Among the 14 patients, recurrence occurred in 3 (21%; 2 (67%) and 1 (33%) patients with OANUMP and oncocytoma, respectively). The proportion of patients with necrosis (66.7% vs 9.1%, <i>p</i> = 0.093), a Helsinki score >5 (66.7% vs 9.1%, <i>p</i> = 0.093), and malignancy by the reticulin algorithm (66.7% vs 9.1%, <i>p</i> = 0.093) were higher in the recurrence group than in the no-recurrence group but were not statistically significant. The percentages of patients with an indeterminate pathological resection margin (100% vs 63.6%, <i>p</i> = 0.192) tended to be higher in the recurrence group than in the no-recurrence group. Of the three patients with recurrence, two had tumor necrosis on the final pathology and were classified as malignant by the reticulin algorithm. One patient diagnosed as OANUMP by the LWB criteria had tumor necrosis and was classified as malignant by the reticulin algorithm and Helsinki scoring system.</p><p><strong>Conclusion: </strong>Necrosis was associated with the recurrence of disease in patients with OANUMP according to the LWB criteria. The absence of necrosis as a major criterion in the current LWB criteria highlights its potential limitation in accurately assessing disease aggressiveness in OANs.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251328186"},"PeriodicalIF":3.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of body mass index and sarcopenia with osteoporosis: a predictive nomogram model for risk assessment.","authors":"Qingling Liu, Shengquan Pan, Ming Tang, Shiwu Yin","doi":"10.1177/20420188251332055","DOIUrl":"https://doi.org/10.1177/20420188251332055","url":null,"abstract":"<p><strong>Objective: </strong>Body mass index (BMI) and sarcopenia are linked to osteoporosis, but the extent to which BMI influences osteoporosis through sarcopenia remains unclear. This study aims to assess the associations between BMI, sarcopenia, and osteoporosis, and to explore the predictive value of their combined biochemical markers for osteoporosis.</p><p><strong>Methods: </strong>We retrospectively collected clinical data from 813 inpatients in the endocrinology department to explore the relationships between serum markers and skeletal muscle mass or BMI, and to evaluate the predictive value of BMI and sarcopenia for osteoporosis. Mediation analysis was employed to examine the associations among BMI, sarcopenia, and osteoporosis. Participants were randomly divided into training (<i>n</i> = 407) and testing (<i>n</i> = 406) sets (5:5). Independent risk factors were identified using least absolute shrinkage and selection operator and logistic regression, leading to the development of a nomogram model. Model evaluation was conducted through receiver operating characteristic curves, confusion matrices, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC).</p><p><strong>Results: </strong>BMI and skeletal muscle mass were negatively correlated with serum 25-hydroxyvitamin D and calcium levels. The \"BMI < 28 and Non-Sarcopenia\" emerged as a protective factor against osteoporosis. Sarcopenia significantly mediated the association between BMI and osteoporosis (46.88%). Gender, age, high-density lipoprotein, alkaline phosphatase, BMI, and sarcopenia emerged as independent predictors of osteoporosis. The area under the curve (AUC) for the training and testing sets was 0.859 and 0.866, respectively, with calibration curves indicating good consistency. DCA and CIC demonstrated clinical net benefits at risk thresholds of 0.02-0.82 and 0.02-0.67. Sankey diagrams and partial AUCs (1.00-0.75 sensitivity and specificity) illustrate the significant negative predictive value of BMI and sarcopenia.</p><p><strong>Conclusion: </strong>Lower BMI and non-sarcopenia are negatively associated with the risk of osteoporosis. In addition, the nomogram demonstrates good predictive value, with a greater negative predictive value of the BMI and sarcopenia.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251332055"},"PeriodicalIF":3.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of vitamin D in the development and progression of diabetic kidney disease: an overview of meta-analyses.","authors":"Ashna Chackochan, Muhammed Rashid, Swetha R Reghunath, Pooja Gopal Poojari, Girish Thunga, Shivashankara Kaniyoor Nagri, Vasudeva Guddattu, Revathi P Shenoy, Vishnu Prasad Shenoy, Leelavathi D Acharya","doi":"10.1177/20420188251319476","DOIUrl":"https://doi.org/10.1177/20420188251319476","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of vitamin D supplementation in the progression of diabetic kidney disease (DKD) remains controversial. Our review tries to provide a comprehensive summary of all the relevant articles in the area to assess the association of vitamin D deficiency with the development of DKD and the effect of vitamin D supplementation on the progression of DKD.</p><p><strong>Methods: </strong>PubMed, Embase, Scopus, Cochrane Library and Web of Science were accessed from inception till June 2024 to obtain all the relevant meta-analyses assessing the function of vitamin D in the onset and prognosis of DKD. The summary data were extracted by two independent reviewers. A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2 tool was used for the assessment of the methodological quality of the included meta-analyses.</p><p><strong>Results: </strong>A total of 4579 articles were obtained from 5 databases in the initial search, of which 8 meta-analyses were included for the evidence synthesis. The methodological quality of the retrieved articles ranged from critically low to high. Serum vitamin D levels were significantly correlated with the prevalence of DKD. The review suggested that vitamin D supplementation could help in reducing proteinuria. However, no such changes were observed in other renal function parameters of DKD patients following vitamin D supplementation.</p><p><strong>Conclusion: </strong>The current evidence indicates that vitamin D supplementation could be beneficial in reducing proteinuria among DKD patients.<b>PROSPERO registration number:</b> CRD42022375194.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251319476"},"PeriodicalIF":3.9,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}